Parse Biosciences Announces Partnership with Japanese Distributor SCRUM Inc.
Parse Biosciences, a leading provider of scalable and accessible single-cell sequencing solutions, has announced a strategic partnership with Tokyo-based SCRUM Inc. to expand its footprint in Japan’s research community. This collaboration is expected to significantly enhance access to Parse’s cutting-edge single-cell sequencing technologies, providing researchers in academia and industry with the tools necessary to drive innovation in biomedical and life sciences research.
Strengthening Single-Cell Research in Japan
The demand for single-cell sequencing technology has surged in recent years as scientists aim to gain deeper insights into cellular heterogeneity, gene expression, and molecular mechanisms underlying various diseases. Japan, recognized as a global leader in biomedical research, is home to many institutions conducting groundbreaking work in genomics, oncology, immunology, and stem cell research.
By partnering with SCRUM, Parse Biosciences is ensuring that researchers in Japan can readily adopt its advanced Evercode single-cell sequencing technology. “Biotech, pharma, and academic researchers throughout Asia are rapidly adopting Parse’s Evercode single-cell sequencing solutions because of their scalability and simplicity,” said Alex Rosenberg, Ph.D., CEO and co-founder of Parse Biosciences. “By partnering with SCRUM, we are ensuring that researchers in Japan can easily leverage Parse’s advanced single-cell sequencing technology to accelerate their discoveries.”
Comprehensive Portfolio of Single-Cell Solutions
As part of this agreement, SCRUM will distribute Parse Biosciences’ full suite of single-cell sequencing solutions throughout Japan. These products offer researchers the ability to conduct high-resolution transcriptomic and immune profiling studies, leading to more precise and reliable data generation. The solutions include:
- Evercode™ Cell and Nuclei Fixation: A technology designed to enable flexible and efficient cell preservation before sequencing, allowing researchers to work with samples at their convenience.
- Evercode™ Whole Transcriptome: A single-cell sequencing solution that provides an in-depth transcriptomic analysis of thousands to millions of cells in a single experiment.
- Evercode™ TCR (T Cell Receptor): A tool designed for immune profiling, enabling researchers to study T-cell receptor diversity and function.
- Evercode™ BCR (B Cell Receptor): A solution that facilitates the analysis of B cell receptor repertoires, crucial for immunology and vaccine research.
- CRISPR Detect: A platform that integrates single-cell sequencing with CRISPR screening, allowing for comprehensive functional genomics studies.
- Gene Select: A targeted gene expression analysis tool that enables efficient profiling of specific genes of interest, optimizing sequencing cost and depth.
- Trailmaker™ for Simplified Data Analysis: A powerful bioinformatics tool designed to simplify single-cell sequencing data processing, ensuring that researchers can extract meaningful insights without requiring extensive computational expertise.
Expanding Global Reach and Market Presence
This partnership is a key milestone in Parse Biosciences’ ongoing global expansion strategy. The company has already made significant inroads into other international markets, including South Korea, Singapore, and India. It has also witnessed strong growth across North America, Europe, Australia, Israel, and New Zealand. With this latest agreement, Parse is reinforcing its commitment to providing cutting-edge single-cell sequencing solutions to researchers worldwide.
Japan has a long-standing history of leadership in biomedical and genomic research. The country’s researchers have played a crucial role in advancing stem cell research, oncology studies, and regenerative medicine. By establishing a local distribution partnership with SCRUM, Parse Biosciences is ensuring that Japanese scientists can seamlessly access and implement its technologies in their ongoing research projects.
The Impact of the Partnership on Japanese Research Community
Kenji Nishimoto, President of SCRUM Inc., expressed enthusiasm about the collaboration, highlighting the potential impact on scientific advancements in Japan. “Japan is at the forefront of single-cell research, with many researchers making influential contributions to the field,” Nishimoto stated. “Our partnership with Parse Biosciences will provide Japan’s researchers with unprecedented access to cutting-edge single-cell sequencing technologies, empowering them to achieve impactful scientific breakthroughs.”
The partnership is expected to catalyze further advancements in precision medicine, drug discovery, and personalized therapeutics. With more researchers gaining access to high-resolution, scalable single-cell sequencing tools, Japan’s research ecosystem is poised to achieve greater discoveries in oncology, neuroscience, developmental biology, and more.
The Future of Single-Cell Sequencing in Japan
Single-cell sequencing has revolutionized the way scientists study biological systems, enabling the analysis of individual cells within complex tissues. As technology continues to evolve, demand for robust and scalable solutions is expected to grow. Parse Biosciences is uniquely positioned to meet this demand with its innovative Evercode platform, which simplifies single-cell analysis without requiring specialized instrumentation.
Through this partnership, Parse Biosciences and SCRUM Inc. are not only enhancing access to state-of-the-art sequencing technology but are also fostering scientific collaboration and knowledge exchange. By empowering Japanese researchers with the latest single-cell sequencing tools, the collaboration has the potential to accelerate discoveries that will impact global healthcare and biomedical research.
In conclusion, the agreement between Parse Biosciences and SCRUM Inc. marks a significant step forward in the expansion of single-cell sequencing solutions in Japan. By providing researchers with the tools they need to conduct high-resolution, large-scale single-cell analyses, this partnership is set to contribute to major scientific advancements in the region and beyond. As single-cell sequencing continues to transform research across multiple disciplines, collaborations like this will play a crucial role in shaping the future of genomics and precision medicine.
